0
$0.00

PNC-27 30mg

Customer Review 0
Rated 5 out of 5

$249.99

Researched Benefits:

  • Facilitates analysis of p53-derived peptide binding to the HDM2-receptor signaling complex
  • Supports investigation into membrane-permeabilization mechanisms within p53-deficient cellular assay models
  • Enables research on HDM2-mediated E3 ubiquitin ligase inhibition and proteasomal degradation
  • Useful for evaluating selective peptide-induced necrosis through specific trans-membrane helical interactions
Share it :
Payment-Icon.png
International Shipment

Your orders are shipped seamlessly between countries

30 Days Warranty

You have the right to return your orders within 30 days.

Secure Payment

Your payments are secure with our private security network.

Description

PNC-27 30mg is a chimeric research peptide explored for its potent, selective cytotoxicity against malignant cells. Engineered from the HDM-2-binding domain of p53 fused to a cell-penetrating leader sequence, PNC-27 disrupts tumor-cell membranes while leaving healthy cells largely unharmed. Synthesized from premium raw materials and rigorously purified, our PNC-27 offers exceptional consistency and reliability for advanced oncological investigations.

Key Features:

  • Manufactured under stringent GMP-compliant conditions to maximize purity and bioactivity.

  • Each lot is subjected to comprehensive HPLC and mass-spectrometry analysis for quality assurance.

  • Supplied as a lyophilized powder to preserve structural integrity during storage and transport.

Applications:

  • Elucidating mechanisms of HDM-2 interaction and membrane pore formation in tumor cells.

  • Assessing selective cytotoxicity and necrosis induction across diverse cancer lines.

  • Investigating synergistic potential with existing chemotherapeutic agents.

Specifications and Documentation

  • Material Safety Data Sheet (MSDS): Coming Soon.

  • Handling and Storage Instructions: Coming Soon.

PNC-27 30mg provides researchers with a precise tool to interrogate targeted anti-cancer strategies, paving the way for deeper insights into tumor-selective therapies.

0